Mark P. Schoenberg
Net Worth

Last updated:

What is Mark P. Schoenberg net worth?

The estimated net worth of Dr. Mark P. Schoenberg is at least $6,046,883 as of 10 Jun 2024. He owns shares worth $2,734,182 as insider, has earned $433,061 from insider trading and has received compensation worth at least $2,879,640 in UroGen Pharma Ltd..

What is the salary of Mark P. Schoenberg?

Dr. Mark P. Schoenberg salary is $479,940 per year as Chief Medical Officer in UroGen Pharma Ltd..

How old is Mark P. Schoenberg?

Dr. Mark P. Schoenberg is 67 years old, born in 1958.

What stocks does Mark P. Schoenberg currently own?

As insider, Dr. Mark P. Schoenberg owns shares in one company:

Company Title Shares Price per share Total value
UroGen Pharma Ltd. (URGN) Chief Medical Officer 144,284 $18.95 $2,734,182

What does UroGen Pharma Ltd. do?

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

URGN logo
URGN
UroGen Pharma Ltd.
$18.95

Mark P. Schoenberg insider trading

UroGen Pharma Ltd.

Dr. Mark P. Schoenberg has made 34 insider trades between 2019-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 122,677 units of URGN stock on 20 Jan 2023. As of 10 Jun 2024 he still owns at least 144,284 units of URGN stock.

Transaction Date Security Shares Price per share Total value Source
Option
Restricted Stock Units 10,000 N/A N/A
Sale
Ordinary Shares 5,153 $13.08 $67,401
Option
Ordinary Shares 10,000 N/A N/A
Sale
Ordinary Shares 12,000 $14.05 $168,600
Sale
Ordinary Shares 1,137 $15.78 $17,942
Sale
Ordinary Shares 758 $15.78 $11,961
Sale
Ordinary Shares 1,894 $15.78 $29,887
Sale
Ordinary Shares 1,137 $15.74 $17,896
Option
Restricted Stock Units 3,333 N/A N/A
Option
Restricted Stock Units 1,333 N/A N/A
Option
Restricted Stock Units 2,000 N/A N/A
Option
Ordinary Shares 2,000 N/A N/A
Sale
Ordinary Shares 1,894 $15.74 $29,812
Option
Ordinary Shares 1,333 N/A N/A
Sale
Ordinary Shares 758 $15.74 $11,931
Option
Ordinary Shares 3,333 N/A N/A
Sale
Ordinary Shares 661 $10.12 $6,689
Option
Restricted Stock Units 500 N/A N/A
Sale
Ordinary Shares 991 $10.12 $10,029
Sale
Ordinary Shares 248 $10.12 $2,510
Option
Restricted Stock Units 2,000 N/A N/A
Option
Restricted Stock Units 2,000 N/A N/A
Option
Restricted Stock Units 1,333 N/A N/A
Option
Restricted Stock Units 1,333 N/A N/A
Option
Ordinary Shares 1,333 N/A N/A
Option
Ordinary Shares 2,000 N/A N/A
Option
Ordinary Shares 500 N/A N/A
Option
Restricted Stock Units 500 N/A N/A
Option
Ordinary Shares 122,677 $5 $613,385
Option
Employee Stock Option (right to buy) 122,677 $5 $613,385
Sale
Ordinary Shares 258 $11.85 $3,057
Option
Restricted Stock Units 500 N/A N/A
Option
Ordinary Shares 500 N/A N/A
Sale
Ordinary Shares 259 $7.81 $2,023
Option
Ordinary Shares 500 N/A N/A
Option
Restricted Stock Units 500 N/A N/A
Option
Restricted Stock Units 500 N/A N/A
Sale
Ordinary Shares 254 $6.62 $1,681
Option
Ordinary Shares 500 N/A N/A
Option
Ordinary Shares 2,000 N/A N/A
Sale
Ordinary Shares 1,099 $7.58 $8,330
Sale
Ordinary Shares 275 $7.58 $2,085
Option
Restricted Stock 2,000 N/A N/A
Option
Restricted Stock Units 500 N/A N/A
Option
Ordinary Shares 500 N/A N/A
Sale
Ordinary Shares 111 $8.09 $898
Option
Restricted Stock Units 209 N/A N/A
Option
Ordinary Shares 209 N/A N/A
Purchase
Ordinary Shares 160 $13.1 $2,096
Sale
Ordinary Shares 258 $17.16 $4,427
Option
Restricted Stock Units 500 N/A N/A
Option
Ordinary Shares 500 N/A N/A
Option
Restricted Stock Units 208 N/A N/A
Sale
Ordinary Shares 107 $16.32 $1,746
Option
Ordinary Shares 208 N/A N/A
Sale
Ordinary Shares 243 $15.64 $3,801
Option
Ordinary Shares 500 N/A N/A
Option
Restricted Stock Units 500 N/A N/A
Option
Ordinary Shares 208 N/A N/A
Option
Restricted Stock Units 208 N/A N/A
Sale
Ordinary Shares 103 N/A N/A
Option
Ordinary Shares 500 N/A N/A
Sale
Ordinary Shares 243 $20 $4,860
Option
Restricted Stock Units 500 N/A N/A
Sale
Ordinary Shares 89 $19.63 $1,747
Option
Restricted Stock Units 209 N/A N/A
Option
Ordinary Shares 209 N/A N/A
Option
Restricted Stock Units 2,000 $22.07 $44,140
Option
Ordinary Shares 2,000 $22.07 $44,140
Sale
Ordinary Shares 1,076 $22.07 $23,747
Option
Ordinary Shares 208 N/A N/A
Sale
Ordinary Shares 100 N/A N/A
Option
Restricted Stock Units 208 N/A N/A
Sale
Ordinary Shares 662 N/A N/A
Option
Ordinary Shares 1,042 N/A N/A
Option
Restricted Stock Units 1,042 N/A N/A
Option
Restricted Stock Units 208 N/A N/A
Option
Ordinary Shares 208 N/A N/A
Sale
Ordinary Shares 101 N/A N/A
Option
Ordinary Shares 1,041 N/A N/A
Sale
Ordinary Shares 348 N/A N/A
Option
Restricted Stock Units 1,041 N/A N/A
Sale
Ordinary Shares 70 N/A N/A
Option
Restricted Stock Units 209 N/A N/A
Option
Ordinary Shares 209 N/A N/A
Sale
Ordinary Shares 349 N/A N/A
Option
Restricted Stock Units 1,042 N/A N/A
Option
Ordinary Shares 1,042 N/A N/A
Sale
Ordinary Shares 70 N/A N/A
Option
Ordinary Shares 208 N/A N/A
Option
Restricted Stock Units 208 N/A N/A
Option
Ordinary Shares 1,042 N/A N/A
Option
Restricted Stock Units 1,042 N/A N/A
Sale
Ordinary Shares 322 N/A N/A
Option
Restricted Stock Units (RSUs) 833 N/A N/A
Option
Ordinary Shares 833 N/A N/A
Option
Ordinary Shares 1,042 N/A N/A
Option
Restricted Stock Units (RSUs) 1,042 N/A N/A
Purchase
Ordinary Shares 1,960 N/A N/A
Option
Ordinary Shares 1,041 N/A N/A
Option
Restricted Stock Units (RSUs) 1,041 N/A N/A
Sale
Ordinary Shares 343 N/A N/A
Option
Ordinary Shares 1,042 N/A N/A
Option
Restricted Stock Units (RSUs) 1,042 N/A N/A
Purchase
Ordinary Shares 272 N/A N/A
Sale
Ordinary Shares 1,991 N/A N/A
Option
Ordinary Shares 1,042 N/A N/A
Option
Restricted Stock Units (RSUs) 1,042 N/A N/A

UroGen Pharma Ltd. key executives

UroGen Pharma Ltd. executives and other stock owners filed with the SEC: